MtBaker schreef op 7 maart 2019 09:10:
A similar consideration might separately be making Galapagos investors uncomfortable as they await readout of the Finch-1 and 3 trials of the Gilead-partnered Jak inhibitor filgotinib, by the end of this quarter. As filgotinib is Gilead's most valuable pipeline hope, a delay would be read as a portent of poor data.